Clinical trial SEAMARK
A Phase 2, Randomized, Open-label study of Encorafenib and Cetuximab plus Pembrolizumab versus Pembrolizumab alone in participants with previously untreated BRAF V600E-Mutant, MSI-H/DMMR Metastatic colorectal cancer (C4221022 - SEAMARK)
| Cancers | |
|---|---|
| Organ | Multiple |
| Trial status | Trial open for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 2 |
| Academic trial | Non |
| Sponsor | Pfizer |
| EudraCT Identifier | 2021-003715-26 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT05217446 |
| Last update |